 |
|
|
| |
Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients ≥65 Years of Age: Results From Phase 2 and 3 Trials
|
| |
| |
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Steven L Flamm1, Edward Gane2, Jean-Francois DuFour3, Vinod Rustgi4, Vincent Bain5, Darrell Crawford6,7, Pietro Andreone8, Tarek Hassanein9, Wlodzimierz Mazur10, Sandra Lovell11, Barbara Da Silva-Tillmann11, Nancy Shulman11, Massimo Puoti 12, Terry D Box13,14, Ira M Jacobson15 1Northwestern Feinberg School of Medicine, Chicago, Illinois, United States; 2Auckland City Hospital, Auckland, New Zealand; 3University Clinic for Visceral Surgery and Medicine, Bern, Switzerland; 4University of Pitt sburgh Medical Center, Pitt sburgh, Pennsylvania, United States; 5University of Alberta, Edmonton, Alberta, Canada; 6Gallipoli Medical Research Foundati on, Brisbane, Australia; 7University of Queensland, Brisbane, Australia; 8University of Bologna, Bologna, Italy; 9Southern California Liver Centers and Southern California Research Center, Coronado, California, United States; 10Medical University of Silesia, Katowice, Poland; 11AbbVie Inc., North Chicago, Illinois, United States; 12AO Ospedale Niguarda Ca Granda, Milan, Italy; 13Clinical Research Centers of America, Murray, Utah, United States; 14University of Utah, Salt Lake City, Utah, United States; 15Weill Cornell Medical College, New York, New York, United States
|
| |
|
|
|
|
|
